Clin2
NCT07171723Possibly a fitRecruiting

Study of LEAP2 on eating control during semaglutide treatment

Obesity &Amp; Overweight

Part of Hormones & metabolism clinical trials.

This study looks at how a natural hormone called LEAP2 affects your appetite and eating behavior while you are taking semaglutide (a weight loss medicine). The results might help doctors understand how to make weight loss treatments even better.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
24 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Between 18 and 65 years old
  • Body mass index (BMI) of 25 or higher
  • Currently taking semaglutide (≥1 mg weekly) for at least 3 months and weight stable (±3% in last 3 months)
  • No diabetes (type 1 or 2) and no diabetes medication (other than semaglutide)
  • No anemia, liver, kidney, or serious stomach/gut problems
  • No regular tobacco or nicotine use; not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05071898Recruiting· Phase 1
Studying how genetics affect response to GLP-1 weight-loss drugs

This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.

Lancaster, Pennsylvania
NCT07770841Recruiting· Phase 3
Oral medication for weight loss study

This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.

Birmingham, Alabama
NCT07424430Not yet recruiting
Long-term study of semaglutide effects on heart, kidney, and metabolic health

This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.

NCT07627074Recruiting
Real-world weight loss study with semaglutide

This study tracks how semaglutide (an injectable medication that reduces appetite) helps adults lose weight in everyday life. Researchers want to understand how well it works and how safe it is for people starting the treatment.

Seattle, Washington
NCT05340868Recruiting
Study body response to oral semaglutide in overweight adults

This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.

Bialystok, Podlaskie Voivodeship
NCT07323134Not yet recruiting
Semaglutide for obesity and gut health

This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.

Hear when a new Obesity &Amp; Overweight trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.